Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Current Assets (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Current Assets for 11 consecutive years, with $777.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 27.82% year-over-year to $777.8 million, compared with a TTM value of $777.8 million through Dec 2025, up 27.82%, and an annual FY2025 reading of $777.8 million, up 27.82% over the prior year.
  • Current Assets was $777.8 million for Q4 2025 at Spyre Therapeutics, up from $504.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $777.8 million in Q4 2025 and bottomed at $44.4 million in Q1 2023.
  • Average Current Assets over 5 years is $299.6 million, with a median of $222.9 million recorded in 2023.
  • The sharpest move saw Current Assets plummeted 52.05% in 2022, then surged 998.08% in 2024.
  • Year by year, Current Assets stood at $98.9 million in 2021, then plummeted by 37.04% to $62.3 million in 2022, then skyrocketed by 448.57% to $341.5 million in 2023, then soared by 78.16% to $608.5 million in 2024, then rose by 27.82% to $777.8 million in 2025.
  • Business Quant data shows Current Assets for SYRE at $777.8 million in Q4 2025, $504.6 million in Q3 2025, and $538.8 million in Q2 2025.